# EDOCH Alternating With DHAP for New Diagnosed Younger MCL

> **NCT02858804** · PHASE4 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 55 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Etoposide
- **DRUG:** Doxorubicin
- **DRUG:** Dexamethasone
- **DRUG:** Vincristine
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Cisplatin
- **DRUG:** Rituximab
- **DRUG:** Thalidomide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02858804
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2019-12
- **Final completion:** 2020-06
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02858804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02858804, "EDOCH Alternating With DHAP for New Diagnosed Younger MCL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02858804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*